Eli Lilly’s $4.2 Billion Day: Inside the Hanmi and Haisco Licensing Deals

Deal Structure

Under the license agreement, Lilly acquires exclusive worldwide rights to develop, manufacture, and commercialize sonefpeglutide outside of South Korea; Hanmi retains rights in its home market . The financial terms include:

• Upfront payment: $75 million .
• Potential milestones: Up to $1.185 billion tied to clinical development, regulatory approvals, and commercialization .
• Total deal value: Up to $1.26 billion, plus royalties .

The deal was Hanmi’s first major out-licensing transaction in six years .

Strategic Rationale

For Lilly, sonefpeglutide provides an opportunity to expand into GLP-2-based therapies for SBS, a condition with limited treatment options, and potentially pursue additional intestinal indications based on the asset’s preclinical and clinical data . The agreement also validates Hanmi’s long-acting platform technology and strengthens its balance sheet for continued R&D .

Haisco Pharmaceutical Group: Multi-Program R&D Collaboration

The Structure

Lilly’s deal with Haisco is larger in scope and more opaque in detail. It is structured as a licensing and research collaboration covering up to five innovative drug target programs across multiple therapeutic areas—none of which have been publicly identified .

Haisco will be responsible for discovering and identifying the targets, while Lilly will lead investigational new drug (IND)-enabling studies, clinical development, and commercialization. Lilly will obtain exclusive worldwide rights to some programs and exclusive rights outside Greater China for others .

Deal Structure

While the upfront payment was initially not publicly disclosed, later reporting specified that Haisco is eligible for up to $87 million in upfront and near-term payments, up to $2.97 billion in downstream milestones, and tiered single-digit royalties on sales . The total potential deal value is approximately $3.0 billion .

The agreement was officially entered on May 29, 2026, and publicly announced alongside the Hanmi deal on June 1 .

Strategic Rationale

For Lilly, the Haisco collaboration represents a broad early-stage pipeline expansion sourced from a Chinese biopharma discovery engine. The company will gain access to novel, undisclosed targets that could span multiple disease areas, with Haisco handling the risk and cost of early discovery . The deal also underscores a continuing pattern of Lilly aggressively pursuing external innovation in 2026 .

For Haisco, the $3 billion headline figure and partnership with a global pharma giant validate its internal discovery capabilities and provide funding for further R&D .

A $4.2 Billion Pipeline Bet

Together, these agreements represent more than $4 billion in potential milestone and deal value for Lilly with two Asian partners on a single day . The Hanmi deal adds a concrete, mid-stage GI asset with near-term Phase 2 data. The Haisco deal adds a portfolio of early-stage programs with significant upside but no disclosed targets, leaving its real value dependent on future scientific and clinical outcomes.